Caprock Group’s Palvella Therapeutics PVLA Stock Holding History

Caprock Group’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-157	Closed	-$86K	–	486
2018 Q1	$86K	Buy	+157	New	+$97.2K	0.02%	435

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Caprock Group's PVLA Position: Q2 2018 in Review

Caprock Group sold out of Palvella Therapeutics (PVLA) in Q2 2018, closing a stake of 157 shares — an estimated $86K sold.

Caprock Group first reported a position in PVLA in Q1 2018 and held it in 1 quarter. The position peaked at $86K in Q1 2018. 115 funds tracked by Wall St. Rank hold PVLA as of Q2 2018.

Caprock Group reported no remaining Palvella Therapeutics position as of Q2 2018 after selling out during the quarter.
Caprock Group sold 157 Palvella Therapeutics shares in Q2 2018, an estimated $86K.
Caprock Group first reported a position in Palvella Therapeutics in Q1 2018 and held it in 1 quarter.
Caprock Group's Palvella Therapeutics position peaked at $86K in Q1 2018.
115 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2018.

Based on Caprock Group's 13F filing for Q2 2018, filed 23 Jul 2018.